Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin + 5-FU intra-arterial infusion with doxorubicin-loaded microsphere embolization for inoperable gastric cardia cancer
ChiCTR1800018480Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Sep 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of oxaliplatin, fluorouracil and doxorubicin in gastric cardia cancer (GEJ) and gastric cancer (GC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: disease control rate, objective response rate and 1 more. Planned start Sep 2018; status: not yet recruiting.
02
Drugs
oxaliplatinfluorouracildoxorubicin
03
Conditions
gastric cardia cancer (GEJ)gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1800018480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018480.